InspireMD, Inc., developer of the CGuard™ Prime carotid stent system for stroke prevention, announced on August 10, 2026, that it will release its second quarter 2026 financial results on Monday, August 17, 2026. The announcement sets the timeline for investors to review the company’s latest financial performance and operational updates regarding its proprietary MicroNet™ mesh technology. In conjunction with the earnings release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and recent highlights.

Conference Call Details

Parties interested in participating in the conference call by phone must register using the online form provided by the company. After registering for the webcast, participants will receive an auto-generated email containing a link to the conference phone number along with a personal pin. Interested participants are encouraged to register more than 15 minutes before the start of the call to ensure timely access.

A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD’s corporate website at https://investors.inspiremd.com . The company routinely posts information that may be important to investors on its website, www.inspiremd.com .

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. The company’s common stock is quoted on Nasdaq under the ticker symbol NSPR. For further investor inquiries, Jeff Warren at LifeSci Advisors serves as the primary contact.

InspireMD Inc (NASDAQ: NSPR) announced on August 7, 2026, that its Compensation Committee approved inducement equity grants totaling 221,666 shares of restricted stock for a new non-executive employee. The grants serve as a material inducement for the individual’s employment with the medical device developer, which specializes in carotid stent systems for stroke prevention. The awards were issued outside the company’s 2021 Equity Incentive Plan, adhering to Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted under InspireMD’s 2024 Inducement Plan, which is designated exclusively for granting equity to individuals who were not previously employees of the company or who have completed a bona fide period of non-employment. The grant date for these shares is August 3, 2026. The Compensation Committee determined that the equity package was essential to securing the new hire, aligning with regulatory requirements for such outside-plan awards.

The restricted stock units are subject to a multi-year vesting schedule contingent upon the recipient’s continued employment with InspireMD through each applicable vesting date. The structure includes three distinct tranches with varying installment frequencies and start dates.

InspireMD develops the CGuard Prime carotid stent system, utilizing its proprietary MicroNet mesh technology to aim for industry-standard acute results and durable long-term outcomes. The company’s common stock is quoted on the Nasdaq stock market under the ticker symbol NSPR.

What the Numbers Show

The vesting structure indicates a significant retention focus, with the largest tranche of 125,000 shares tied to the longest service period. By staggering the vesting dates across multiple years, the company aligns the new employee’s interests with long-term operational stability rather than short-term gains. This approach is consistent with standard compensation practices for non-executive roles requiring specialized expertise in the medical device sector.